Search results
Results from the WOW.Com Content Network
Deudomperidone (developmental code name CIN-102; also known as deuterated domperidone) is a dopamine antagonist medication which is under development in the United States for the treatment of gastroparesis. [1] [2] [3] It acts as a selective dopamine D 2 and D 3 receptor antagonist and has peripheral selectivity.
The medication provides relief from nausea by blocking D 2 receptors in the chemoreceptor trigger zone and from gastrointestinal symptoms by blocking D 2 receptors in the gut. [ 20 ] [ 2 ] It blocks D 2 receptors in the lactotrophs of the anterior pituitary gland increasing release of prolactin which in turn increases lactation .
Velusetrag (INN, [1] USAN; previously known as TD-5108) is an experimental drug candidate for the treatment of gastric neuromuscular disorders including gastroparesis, and lower gastrointestinal motility disorders including chronic idiopathic constipation and irritable bowel syndrome. [2]
Among patients taking the drugs, 0.53% were diagnosed with gastroparesis — about 750 out of nearly 150,000 patients. “Patients need to be informed about these side effects before treatment is ...
Gastroparesis (gastro- from Ancient Greek γαστήρ – gaster, "stomach"; and -paresis, πάρεσις – "partial paralysis") is a medical disorder of ineffective neuromuscular contractions (peristalsis) of the stomach, resulting in food and liquid remaining in the stomach for a prolonged period of time.
Levosulpiride, sold under the brand names Dislep and Sulpepta among others, is a dopamine antagonist medication which is used in the treatment of psychotic disorders like schizophrenia, major depressive disorder, nausea and vomiting, and gastroparesis.
These medications include Mounjaro, which is FDA-approved to treat type 2 diabetes, and Zepbound, which is designed for weight loss. The Zepbound website says that people lost up to 48 pounds ...
Tradipitant underwent phase II clinical trials assessing its utility in the treatment of gastroparesis the results of which were announced on December 3, 2018. [7] In a study performed over 4 weeks with a patient population of 141 patients, Tradipitant met its primary endpoint of decreased nausea scores as recorded in daily patient diaries. It ...